93 related articles for article (PubMed ID: 10415768)
1. Metalloproteinases and tissue inhibitors of matrix-metalloproteinases in plasma of patients with prostate cancer and in prostate cancer tissue.
Lein M; Nowak L; Jung K; Laube C; Ulbricht N; Schnorr D; Loening SA
Ann N Y Acad Sci; 1999 Jun; 878():544-6. PubMed ID: 10415768
[No Abstract] [Full Text] [Related]
2. Serum metalloproteinases and their inhibitors: markers for malignant potential.
Baker T; Tickle S; Wasan H; Docherty A; Isenberg D; Waxman J
Br J Cancer; 1994 Sep; 70(3):506-12. PubMed ID: 8080738
[TBL] [Abstract][Full Text] [Related]
3. Matrix metalloproteinase-2 in blood does not indicate the progression of prostate cancer.
Jung K; Laube C; Lein M; Türk I; Lichtinghagen R; Rudolph B; Schnorr D; Loening SA
Int J Cancer; 1998 Oct; 78(3):392-3. PubMed ID: 9766579
[No Abstract] [Full Text] [Related]
4. High levels of tissue inhibitor of metalloproteinase-1 predict poor outcome in patients with breast cancer.
McCarthy K; Maguire T; McGreal G; McDermott E; O'Higgins N; Duffy MJ
Int J Cancer; 1999 Feb; 84(1):44-8. PubMed ID: 9988231
[TBL] [Abstract][Full Text] [Related]
5. Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase-1 and the complex of metalloproteinase-1/tissue inhibitor in plasma of patients with prostate cancer.
Jung K; Nowak L; Lein M; Priem F; Schnorr D; Loening SA
Int J Cancer; 1997 Apr; 74(2):220-3. PubMed ID: 9133459
[TBL] [Abstract][Full Text] [Related]
6. [Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma].
Lein M; Nowak L; Jung K; Koenig F; Schnorr D; Loening SA
Urologe A; 1998 Jul; 37(4):377-81. PubMed ID: 9738289
[TBL] [Abstract][Full Text] [Related]
7. Matrix metalloproteinases as diagnostic (MMP-13) and prognostic (MMP-2, MMP-9) markers of prostate cancer.
Morgia G; Falsaperla M; Malaponte G; Madonia M; Indelicato M; Travali S; Mazzarino MC
Urol Res; 2005 Feb; 33(1):44-50. PubMed ID: 15517230
[TBL] [Abstract][Full Text] [Related]
8. Elevated plasma gelatinase A (MMP-2) activity is associated with quiescent Crohn's Disease.
Kossakowska AE; Medlicott SA; Edwards DR; Guyn L; Stabbler AL; Sutherland LR; Urbanski SJ
Ann N Y Acad Sci; 1999 Jun; 878():578-80. PubMed ID: 10415778
[No Abstract] [Full Text] [Related]
9. [Matrix metalloproteinases and their inhibitors in ovarian cancer progression--diagnostic and therapeutic implications].
Stettner R; Bogusiewicz M; Rechberger T
Ginekol Pol; 2009 Jan; 80(1):47-53. PubMed ID: 19323060
[TBL] [Abstract][Full Text] [Related]
10. Expression of matrix metalloproteinase-7 and tissue inhibitor of metalloproteinase-1 in human prostate.
Hashimoto K; Kihira Y; Matuo Y; Usui T
J Urol; 1998 Nov; 160(5):1872-6. PubMed ID: 9783977
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical expression of matrix metalloproteinase-9 and inhibitor of matrix metalloproteinase-1 in prostate adenocarcinoma.
Babichenko II; Andriukhin MI; Pulbere S; Loktev A
Int J Clin Exp Pathol; 2014; 7(12):9090-8. PubMed ID: 25674294
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical studies of the expression of matrix metalloproteinase-2 and metalloproteinase-9 in human prostate cancer.
Zeng H; Xiao Y; Lu G; Chen Y
J Huazhong Univ Sci Technolog Med Sci; 2003; 23(4):373-4, 379. PubMed ID: 15015639
[TBL] [Abstract][Full Text] [Related]
13. [Comment on Grond, A., M. Ostermann-Myrau: Benign and malignant diseases of the prostate].
Grond A
Versicherungsmedizin; 1995 Apr; 47(2):66-7. PubMed ID: 7539193
[No Abstract] [Full Text] [Related]
14. Matrix metalloproteinases, their endogenous inhibitors, and microbial activators in gingival crevicular fluid and saliva of HIV(+)-subjects.
Salo T; Sorsa T; Lauhio A; Konttinen YT; Ainamo A; Kjeldsen L; Borregaard N; Ranta H; Lähdevirta J
Ann N Y Acad Sci; 1994 Sep; 732():476-8. PubMed ID: 7978843
[No Abstract] [Full Text] [Related]
15. Measurement of matrix metalloproteinases and tissue inhibitors of metalloproteinases in blood and tissues. Clinical and experimental applications.
Zucker S; Hymowitz M; Conner C; Zarrabi HM; Hurewitz AN; Matrisian L; Boyd D; Nicolson G; Montana S
Ann N Y Acad Sci; 1999 Jun; 878():212-27. PubMed ID: 10415733
[TBL] [Abstract][Full Text] [Related]
16. Matrix metalloproteinases-1, -3, and -8 in adult periodontitis in situ. An immunohistochemical study.
Ingman T; Sorsa T; Michaelis J; Konttinen YT
Ann N Y Acad Sci; 1994 Sep; 732():459-61. PubMed ID: 7978839
[No Abstract] [Full Text] [Related]
17. Expression of metalloproteinases (MMP-1, MMP-2, and MMP-9) and their inhibitors (TIMP-1 and TIMP-2) in schistosomal portal fibrosis.
Gomez DE; De Lorenzo MS; Alonso DF; Andrade ZA
Am J Trop Med Hyg; 1999 Jul; 61(1):9-13. PubMed ID: 10432047
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of matrix metalloproteinases (MMP) 1 and 2, and tissue inhibitor of metalloproteinase 2 (TIMP 2) in stage I and II endometrial cancer.
Moser PL; Hefler L; Tempfer C; Neunteufel W; Kieback DG; Gitsch G
Anticancer Res; 1999; 19(3B):2365-7. PubMed ID: 10472357
[TBL] [Abstract][Full Text] [Related]
19. Metalloproteinases and tissue inhibitors of metalloproteinases.
Toi M; Ishigaki S; Tominaga T
Breast Cancer Res Treat; 1998; 52(1-3):113-24. PubMed ID: 10066076
[TBL] [Abstract][Full Text] [Related]
20. Serum matrix metalloproteinase-2 and its density in men with prostate cancer as a new predictor of disease extension.
Gohji K; Fujimoto N; Hara I; Fujii A; Gotoh A; Okada H; Arakawa S; Kitazawa S; Miyake H; Kamidono S; Nakajima M
Int J Cancer; 1998 Feb; 79(1):96-101. PubMed ID: 9495366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
